Pricing is often one of the most carefully designed elements of a pharmaceutical strategy.
Global teams build detailed pricing corridors.
Reference markets are selected.
Assumptions are stress-tested.
On paper, the logic is sound.
But across Southeast Asia and ANZ, one reality consistently emerges:
Pricing strategies that work globally often break locally.
The Assumption of Pricing Consistency
At a global level, pricing is typically approached with a degree of consistency.
- Reference pricing frameworks are applied
- International benchmarks are used
- Price alignment across markets is maintained
The objective is clear:
Protect global price integrity.
But in practice, this assumption does not always hold.
Because pricing is not just a financial decision.
It is shaped by market realities.
ANZ: Structured, Transparent — but Stringent
Markets like Australia and New Zealand operate highly structured pricing environments.
- Strong health technology assessment (HTA) processes
- Centralised reimbursement systems
- Clear evaluation frameworks
Pricing decisions are closely tied to:
- Clinical value
- Cost-effectiveness
- Budget impact
In Australia, for example, reimbursement outcomes are heavily influenced by national-level evaluations, where evidence and value demonstration are critical.
In New Zealand, funding decisions are even more constrained, with prioritisation driven by limited budgets.
Implication:
Pricing is not about how high you can go.
It is about whether you can justify the price at all.
Southeast Asia: Fragmented, Diverse, and Highly Variable
In contrast, Southeast Asia presents a very different pricing landscape.
Across the region, there is no single model.
You see:
- Government-regulated pricing in some markets
- Tender-driven pricing in others
- Significant private market influence in many countries
- High out-of-pocket expenditure across large patient populations
For example:
- In Indonesia, pricing is shaped by national health insurance and tenders
- In Thailand, multiple public schemes influence pricing and access
- In the Philippines, private sector pricing plays a major role
- In Singapore, pricing is more structured but still influenced by institutional and payer considerations
Implication:
Pricing strategies cannot be standardised.
They must be market-specific and highly adaptive.
The Role of Affordability vs Value
One of the biggest disconnects I’ve observed is the tension between:
- Value-based pricing (global perspective)
- Affordability-driven pricing (local reality)
In ANZ:
- Strong emphasis on cost-effectiveness
- Formal evaluation frameworks
- Clear linkage between value and price
In Southeast Asia:
- Greater variability in willingness to pay
- Higher sensitivity to affordability
- Access often constrained by funding mechanisms
This creates a fundamental challenge:
A price justified globally may not be accessible locally.
Case Comparison: Australia vs Singapore vs Thailand vs Indonesia
To illustrate how pricing realities differ across the region, consider four markets: Australia, Singapore, Thailand, and Indonesia.
Australia
- Structured pricing and reimbursement framework
- Strong HTA-driven decision-making
- Clear evaluation criteria
- High emphasis on cost-effectiveness
Outcome:
Pricing is disciplined, transparent, and evidence-driven — but access is tightly controlled and dependent on reimbursement approval.
Singapore
- Highly structured healthcare system
- Strong regulatory alignment with global standards
- Institutional and payer-driven pricing decisions
- High private sector influence alongside government frameworks
Outcome:
Pricing is relatively structured and aligned with global benchmarks, but still requires alignment with institutional expectations and patient affordability considerations.
Thailand
- Multi-tiered public healthcare system
- National essential medicines lists guiding access
- Combination of government influence and institutional decision-making
- Increasing role of health economic evaluation
Outcome:
Pricing sits between structure and flexibility — requiring alignment with public system requirements while navigating differences across schemes.
Indonesia
- Pricing influenced by national health insurance and tenders
- Strong emphasis on affordability
- Significant role of public procurement
- Variability across regions and channels
Outcome:
Pricing must be highly competitive and adaptable — often requiring significant localisation and trade-offs.
The Real Insight
The difference is not just in price levels.
It is in:
- Who determines price
- How value is assessed
- How access is granted
Australia is structured and evidence-driven.
Singapore is structured but institutionally influenced.
Thailand is scheme-dependent and evolving.
Indonesia is affordability-driven and decentralised.
And that fundamentally changes how pricing strategies must be designed.
The Hidden Risk: Global Price Protection vs Local Access
A common tension in global organisations is the need to:
- Protect international price benchmarks
- Avoid downward price referencing
- Maintain consistency across markets
But this can come at a cost.
If pricing is set too high relative to local realities:
- Access is limited
- Uptake is slow
- Commercial potential is not realised
In some cases, the issue is not the product.
It is the pricing strategy.
What Successful Organisations Do Differently
The organisations that succeed in Southeast Asia and ANZ:
- Design pricing strategies market by market
- Balance global price integrity with local access realities
- Use differentiated pricing approaches where needed
- Align pricing with reimbursement and access pathways
- Engage early with local stakeholders
They recognise that pricing is not just a number.
It is a market access and commercial strategy.
My Reflection
Across Southeast Asia and ANZ, pricing is not simply about value.
It is about what the system can absorb, what patients can afford, and how access is structured.
The companies that succeed are not those that insist on global consistency.
They are the ones that understand where — and how — to adapt.
Because in this region:
A price that works globally does not guarantee access locally.
How Lumeos Can Help
For life sciences companies evaluating opportunities across Southeast Asia, pricing strategy must be considered alongside market attractiveness, access conditions and commercialization priorities. Lumeos Entry™ supports informed market-entry decisions, while Lumeos Launch™ addresses the strategic considerations involved in bringing products successfully to market.